Health Canada Signals Regulatory Flexibility for Low-Risk Non‑Prescription Drugs 

Health Canada has announced its intention to introduce a Ministerial Class Exemption Order aimed at reducing regulatory barriers for certain low-risk non-prescription drugs (NPDs). The proposal represents a significant step in modernizing Canada’s regulatory framework for products that are widely used for self-care and the treatment or prevention of common conditions. [Notice of…Canada.ca] 

Currently, all drugs containing new medicinal ingredients—whether prescription or non-prescription—are subject to Division 8 of the Food and Drug Regulations. This pathway is designed for higher-risk products and requires extensive data submissions, lengthy review timelines (up to approximately 300 days), and substantial costs exceeding $600,000. While appropriate for innovative or higher-risk therapies, this approach has created a disproportionately high burden for lower-risk, “cosmetic-like” NPDs such as sunscreens, oral care products, and anti-dandruff treatments. [Notice of…Canada.ca] 

Health Canada acknowledges that these requirements have limited the ability of companies to introduce new low-risk products, particularly those already marketed safely in other jurisdictions. Stakeholder engagement, including collaboration with international partners such as the European Union, has highlighted these barriers as a constraint on product availability and consumer choice in Canada. [Notice of…Canada.ca] 

Proposed Regulatory Approach 

The proposed Order would exempt certain low-risk NPDs listed on Health Canada’s “List D” from Division 8 requirements, provided they comply with an existing Health Canada monograph. Instead of undergoing the new drug approval process, these products could be authorized under Division 1 through the issuance of a Drug Identification Number (DIN), without requiring a Notice of Compliance. [Notice of…Canada.ca] 

List D encompasses a broad range of commonly used products, including acne treatments, sunscreens, toothpastes, antiseptic skin cleansers, throat lozenges, and diaper rash products. These products are generally recognized as having well-established safety and efficacy profiles when used according to clearly defined parameters. [Notice of…Canada.ca] 

Health Canada also intends to expand and update its monograph system over time, allowing additional medicinal ingredients—particularly those supported by international evidence—to qualify for this streamlined pathway. 

Implications for Industry and Market Access 

For regulated companies, the proposed Order has the potential to significantly reduce time-to-market, development costs, and regulatory complexity. It may encourage greater market participation, including entry by international manufacturers and increased domestic production. The initiative is also expected to support supply chain resilience by diversifying sources beyond the United States, which currently accounts for the majority of imports in these categories. [Notice of…Canada.ca] 

For consumers, improved access to a wider range of NPDs could enhance self-care options for prevalent conditions such as acne, oral health issues, and sun protection—areas where public health data indicate ongoing unmet needs. 

Policy Context and Next Steps 

This initiative forms part of Health Canada’s broader Red Tape Reduction agenda and ongoing efforts to modernize regulatory oversight for non-prescription products. The exemption would remain in effect until planned amendments to Part C of the regulations come into force. [Notice of…Canada.ca] 

Health Canada is currently seeking stakeholder feedback, including input on new ingredients that could be incorporated into monographs. Comments are invited until July 14, 2026. 

Outlook 

If implemented, the proposed Order represents a meaningful shift toward a more risk-proportionate regulatory model. It is likely to benefit both industry stakeholders and Canadian consumers by improving access, fostering innovation, and maintaining appropriate safeguards for product safety and efficacy. The Notice can be read at the link below: 

Notice of intent to publish a Ministerial Order to exempt certain low-risk non-prescription drugs from Division 8 provisions in the Food and Drugs Regulations